Total submissions: 1
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ambry Genetics | RCV002319618 | SCV001177755 | likely pathogenic | Hereditary cancer-predisposing syndrome; Cardiovascular phenotype | 2018-08-13 | criteria provided, single submitter | clinical testing | The c.2850_2850+2dupGGT variant results from a duplication of 3 nucleotides at the boundary of coding exon 21 and intron 21 of the NF1 gene. This nucleotide region is highly conserved in available vertebrate species. Using the BDGP and ESEfinder splice site prediction tools, this alteration is predicted to abolish the native donor splice site; however, direct evidence is unavailable. Alterations that disrupt the canonical splice site are expected to cause aberrant splicing, resulting in an abnormal protein or a transcript that is subject to nonsense-mediated mRNA decay. As such, this alteration is classified as likely pathogenic. |